Home » Newsletters » BioWorld Science

BioWorld Science

May 24, 2006

View Archived Issues

Valproic acid induces apoptosis in prostate cancer cells

Telbivudine superior to adefovir in chronic hepatitis B

Pooled data allow subgroup analysis of lubiprostone efficacy in constipation

Studies examine celgosivir pharmacokinetics, activity and tolerability

SkyePharma to develop controlled-release formulation of First Horizon's Sular

Repros updates progress of Androxal study

Enrollment slower than expected in Proellex studies

Dyax grants phage display libraries license to Icos for antibody discovery

GeoVax begins studies of HIV/AIDS vaccine

SPA agreement for phase III study of CoFactor

Ramelteon shows potential for circadian phase shifting

ProEthic begins phase III study for PRO-513 for migraines

Orphan drug designation for Talotrexin for ALL

XP-19986 reduces number of reflux episodes in GERD patients

CRx-102 reduces CRP in human inflammatory model

Unusually high placebo response rate causes failure of bicifadine phase III trial

Debiopharm and TcLand sign inlicensing option agreement for sc28AT

Prous Science webcasts AUA Annual Meeting in Atlanta

Tranzyme presents new in vivo data on novel gastrointestinal drug candidates

J&J develops novel leukotriene A4 hydrolase inhibitors for IBD

Early studies with alpha4 integrin antagonist T-728 suggest possible use in IBD

Inhibition of PI3K/Akt signaling appears promising to treat prostate cancer

Adenosine A2A receptor antagonist MSX-3 shows activity in parkinsonian motor effects

Vernalis presents preclinical, clinical update on BIIB-014 for Parkinson's disease

New antiinfective agents reported in recent patents

New treatment options for cardiovascular diseases disclosed in recent patent literature

Recent Merz patent discloses novel agents for drug addiction